- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cynata Therapeutics Ltd (CYP)
Cynata Therapeutics Ltd stock price live, this page displays ASX CYP stock exchange data. View the CYP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cynata Therapeutics Ltd real time stock price chart below.
What Is the Cynata Therapeutics Ltd Stock Price Today?
The Cynata Therapeutics Ltd stock price today is 0.185.
What Is the Stock Symbol for Cynata Therapeutics Ltd?
The stock symbol for Cynata Therapeutics Ltd is ""CYP.""
What Stock Exchange Does Cynata Therapeutics Ltd Trade On?
Cynata Therapeutics Ltd is listed and trades on the Sydney stock exchange.
Is Cynata Therapeutics Ltd a Good Stock to Buy?
Determining whether Cynata Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYP quote. (ISIN: AU000000CYP7)
What Is the Cynata Therapeutics Ltd Stock Price Today?
The Cynata Therapeutics Ltd stock price today is 0.185.
What Is the Stock Symbol for Cynata Therapeutics Ltd?
The stock symbol for Cynata Therapeutics Ltd is ""CYP.""
What Stock Exchange Does Cynata Therapeutics Ltd Trade On?
Cynata Therapeutics Ltd is listed and trades on the Sydney stock exchange.
Is Cynata Therapeutics Ltd a Good Stock to Buy?
Determining whether Cynata Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYP quote. (ISIN: AU000000CYP7)
0.185
+0.015(+8.82%)
Closed·
Fair Value
An estimate of a Cynata Therapeutics Ltd's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.170
0.185
52 wk Range
0.140
0.285
CYP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CYP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Cynata Therapeutics Ltd's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.1700.185
52 wk Range
0.1400.285
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
CYP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Cynata Therapeutics Ltd's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Cynata Therapeutics Ltd Company Profile
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Compare CYP to Peers and Sector
Metrics to compare | CYP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −5.7x | −0.5x | |
PEG Ratio | −0.11 | −0.02 | 0.00 | |
Price/Book | 3.5x | 2.6x | 2.6x | |
Price / LTM Sales | 23.4x | 13.3x | 3.3x | |
Upside (Analyst Target) | 331.4% | 263.0% | 43.5% | |
Fair Value Upside | Unlock | 14.8% | 6.8% | Unlock |
Earnings
Latest Release
Feb 27, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
1.97M / --
FAQ
What Stock Exchange Does Cynata Therapeutics Ltd Trade On?
Cynata Therapeutics Ltd is listed and trades on the Sydney Stock Exchange stock exchange.
What Is the Stock Symbol for Cynata Therapeutics Ltd?
The stock symbol for Cynata Therapeutics Ltd is "CYP."
What Is the Cynata Therapeutics Ltd Market Cap?
As of today, Cynata Therapeutics Ltd market cap is 41.80M.
What Is Cynata Therapeutics Ltd's Earnings Per Share (TTM)?
The Cynata Therapeutics Ltd EPS (TTM) is -0.05.
From a Technical Analysis Perspective, Is CYP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Cynata Therapeutics Ltd Stock Split?
Cynata Therapeutics Ltd has split 3 times.
How Many Employees Does Cynata Therapeutics Ltd Have?
Cynata Therapeutics Ltd has 2 employees.
What is the current trading status of Cynata Therapeutics Ltd (CYP)?
As of 09 Aug 2025, Cynata Therapeutics Ltd (CYP) is trading at a price of 0.19, with a previous close of 0.17. The stock has fluctuated within a day range of 0.17 to 0.19, while its 52-week range spans from 0.14 to 0.29.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.